COMMON STOCK | 6. COMMON STOCK a) Stock Options The Company has a rolling stock option plan (the “Plan”) whereby the Company may grant stock options to executive officers and directors, employees, and consultants at an exercise price to be determined by the board of directors, provided the exercise price is not lower than the greater of (i) the last closing price of the Company’s common shares on the TSX and (ii) the volume weighted average closing price of the Company’s common shares on the TSX for the five days immediately prior to the date of grant. The Plan provides for the issuance of up to 10% of the Company’s issued Common Shares as at the date of grant with each stock option having a maximum term of ten years. The board of directors has the exclusive power over the granting of options and their vesting provisions. Stock option transactions are summarized as follows: Number of Weighted Balance, June 30, 2016 11,465,000 $ 0.69 Granted 710,000 0.96 Exercised - - Cancelled/expired (150,000 ) 0.62 Balance, December 31, 2016 12,025,000 $ 0.71 The following table summarizes the information and assumptions used to determine option costs for the six-month period ended December 31, 2016: Fair value per option granted during the period (C$) $ 0.50 Risk-free interest rate 0.75 % Expected dividend yield 0 % Expected stock price volatility (historical basis) 97.2 % Expected option life in years 2.15 The following table summarizes information about stock options outstanding at December 31, 2016: Exercise Expiry date Number Aggregate Number Aggregate $ 0.50 May 9, 2017 370,000 $ 93 370,000 $ 93 $ 0.62 January 19, 2021 5,425,000 705 2,712,500 353 $ 0.65 May 20, 2017 50,000 5 50,000 5 $ 0.65 July 28, 2017 1,250,000 125 1,250,000 125 $ 0.76 September 2, 2017 500,000 - 500,000 - $ 0.80 December 22, 2017 3,220,000 - 3,220,000 - $ 0.94 April 28, 2018 500,000 - 500,000 - $ 0.96 July 21, 2021 710,000 - - - Balance December 31, 2016 12,025,000 $ 928 8,602,500 $ 576 The aggregate intrinsic value in the preceding table represents the total intrinsic value, based on the Company’s closing stock price of C$0.75 as of December 31, 2016, which would have been received by the option holders had all option holders exercised their options as of that date. In-the-money options vested and exercisable as of December 31, 2016, totaled 4,382,500. As of December 31, 2016, there was $160 of unrecognized compensation cost related to unvested share-based compensation arrangements granted under the Plan. The cost is expected to be recognized over a remaining weighted average period of approximately 1.0 years. b) Warrants Warrant transactions are summarized as follows: Warrants Weighted average Balance June 30, 2016 22,733,685 $ 0.74 Granted - - Exercised (3,447,137 ) 0.65 Expired (4,114,353 ) 0.65 Balance, December 31, 2016 15,172,195 $ 0.79 At December 31, 2016, the Company has outstanding exercisable warrants, as follows: Number Exercise Expiry Date 182,910 $ 0.85 February 27, 2017 2,714,000 1.00 February 27, 2017 3,125,000 0.72 December 22, 2018 9,150,285 0.75 January 19, 2019 15,172,195 | 8. COMMON STOCK a) Issuances 2016 Issuances On January 19, 2016, the Company closed a private placement and issued 9,074,835 units (each a “Unit”) at a price of C$0.57 per Unit, resulting in total gross proceeds of $3,750. Each Unit consisted of one common share of the Company and one transferable common share purchase warrant (a “Private Placement Warrant”). Each Private Placement Warrant is exercisable to acquire one additional common share of the Company for a period of three years at a price of C$0.75 per common share. In addition, the Company issued 75,450 broker warrants at closing, under the same terms as a Private Placement Warrant. The fair value of the broker warrants of $15 was estimated based on the Black-Scholes pricing model using a risk free interest rate of 0.75%, an expected dividend yield of 0%, a volatility of 100.13%, and an expected life of 3.0 years. 2015 Issuances In February 2015 the Company announced it had closed a partially brokered and partially non-brokered private placement of 2,914,000 special warrants (“2015 Warrants”) at an issue price of C$0.75 to raise aggregate gross proceeds of $1,722. Each 2015 Warrant is exchangeable at any time after the closing date of the offering into one unit of the Company; each unit consists of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder to acquire one additional common share at a price of C$1.00 per share until February 27, 2017. The Company filed a prospectus and obtained the required receipt for that prospectus on March 23, 2015 and qualified the distribution of 2,914,000 2015 Warrants which were deemed exercised on March 30, 2015. The agent, Mackie Research Capital Corporation ("MRCC") received a cash commission equal to 6.5% of the gross proceeds of the brokered portion of the offering being $112 and 182,910 compensation warrants. The broker warrants are exercisable into common shares at a price C$0.85 per share until February 27, 2017. The fair value of the agent warrants of $79 was estimated based on the Black-Scholes pricing model using a risk free interest rate of 1.25%, an expected dividend yield of 0%, a volatility of 100.95%, and an expected life of 2.0 years. Total cash issue costs including agents' commission, legal and filing fees were $230. In November 2014 the Company announced it had closed a partially brokered and partially non-brokered private placement of 19,245,813 special warrants (“2014 Special Warrants”) at an issue price of C$0.55 to raise aggregate gross proceeds of $8,846. Each 2014 Special Warrant is exchangeable at any time after the closing date of the offering into one unit of the Company; each unit consists of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder to acquire one additional common share at a price of C$0.65 per share until November 10, 2016. The Company filed a prospectus and obtained the required receipt for that prospectus on January 14, 2015 and qualified the distribution of 19,245,813 2014 Special Warrants which were deemed exercised on January 19, 2015. The agent, MRCC received a cash commission equal to 6.5% of the gross proceeds of the brokered portion of the offering and 205,304 non-transferable compensation units. The broker warrants are exercisable into units having the same terms as the units issued under the Offering. Each unit entitles the agent to purchase a unit at a price of C$0.55 each. Each unit consists of one common share and one warrant exercisable at a price of C$0.65 per share until November 10, 2016. The fair value of the agent warrants of $108 was estimated based on the Black Scholes pricing model using a risk free interest rate of 1.25%, an expected dividend yield of 0%, a volatility of 108.9%, and an expected life of 2.0 years. Total cash issue costs including agents' commission, legal and filing fees was $300. b) Stock Options The Company has a rolling stock option plan (the “Plan”) whereby the Company may grant stock options to executive officers and directors, employees, and consultants at an exercise price to be determined by the board of directors, provided the exercise price is not lower than the market value on the date of grant. The Plan provides for the issuance of up to 10% of the Company’s issued common shares as at the date of grant with each stock option having a maximum term of five years. The board of directors has the exclusive power over the granting of options and their vesting provisions. Stock option transactions are summarized as follows: Number of Weighted Balance, July 1, 2014 7,060,000 $ 0.19 Granted 7,320,000 0.76 Exercised (6,250,000 ) 0.20 Cancelled/expired (25,000 ) 0.30 Balance, June 30, 2015 8,105,000 0.69 Granted 5,875,000 0.62 Exercised (1,415,000 ) 0.38 Cancelled/expired (1,100,000 ) 0.75 Balance June 30, 2016 11,465,000 $ 0.69 Number of options currently exercisable 5,765,000 $ 0.75 The following table summarizes the information and assumptions used to determine option costs: Year ended June 30, 2016 2015 Fair value per option granted during the period (C$) $ 0.30 $ 0.42 Risk-free interest rate 0.75 % 1.25 % Expected dividend yield 0 % 0 % Expected stock price volatility (historical basis) 98.2 % 105.6 % Expected option life in years 2.15 2.15 The following table summarizes information about stock options outstanding at June 30, 2016: Exercise Expiry date Number Aggregate Number Aggregate $ 0.50 May 9, 2017 370,000 133 370,000 133 $ 0.62 January 19, 2021 5,575,000 1,338 - - $ 0.65 May 20, 2017 50,000 11 50,000 11 $ 0.65 July 28, 2017 1,250,000 263 1,250,000 263 $ 0.76 September 2, 2017 500,000 50 500,000 50 $ 0.80 December 22, 2017 3,220,000 193 3,220,000 193 $ 0.94 April 28, 2018 500,000 - 375,000 - Balance June 30, 2016 11,465,000 $ 1,988 5,765,000 $ 650 The aggregate intrinsic value in the preceding table represents the total intrinsic value, based on the Company’s closing stock price of C$0.86 as of June 30, 2016, which would have been received by the option holders had all option holders exercised their options as of that date. The total number of in-the-money options vested and exercisable as of June 30, 2016 was 5,390,000. The total intrinsic value of options exercised during the year ended June 30, 2016 was $322. As of June 30, 2016, there was $328 of unrecognized compensation cost related to unvested share-based compensation arrangements granted under the Plan. The cost is expected to be recognized over a weighted average period of approximately one year. c) Warrants Warrant transactions are summarized as follows: Warrants Weighted average Balance, July 1, 2014 1,064,140 $ 0.25 Granted: Warrants: November financing 19,245,813 0.65 Warrants: March financing 2,914,000 1.00 Agents' warrants: November financing 205,304 0.55 Agents' warrants: November financing 205,304 0.65 Agents' warrants: March financing 182,910 0.85 Agents' advisory warrants* 750,000 0.55 Agents' sponsorship warrants** 250,000 0.60 ThyssenKrupp offtake agreement*** 8,569,000 0.67 Exercised (5,125,805 ) 0.35 Expired - - Balance, June 30, 2015 28,260,666 0.73 Granted: Lind Warrants 3,125,000 0.72 January Private Placement 9,074,835 0.75 Broker warrants: December Private Placement 75,450 0.75 Advisory Warrants* 750,000 0.65 Sponsorship warrants** 250,000 0.65 Exercised (12,549,309 ) 0.65 Expired (7,068,500 ) 0.67 Balance June 30, 2016 21,918,142 $ 0.75 * Pursuant to a financial services advisory agreement with Mackie Research Capital Corporation (“MRCC”) the Company issued 500,000 advisory warrants on December 4, 2014 and 250,000 advisory warrants on January 14, 2015. Each advisory warrant entitled MRCC to purchase a unit of the Company at a price of C$0.55 each, on or before December 4, 2016. Each such unit consisted of one Common Share and one warrant exercisable at a price of C$0.65 per share until December 4, 2016. These units were exercised during the year ended June 30, 2016, resulting in the granting of these additional 750,000 warrants. ** Pursuant to a sponsorship agreement between MRCC and the Company in connection with the Company's graduation to the Toronto Stock Exchange, the Company issued 250,000 sponsorship warrants on January 14, 2015, entitling MRCC to purchase units of the Company at C$0.60 per unit until January 14, 2017. Each such unit consisted of one Common Share and one warrant exercisable at C$0.65 per share until January 14, 2017. These units were exercised during the year ended June 30, 2016, resulting in the granting of these additional 250,000 warrants. *** The Company entered into an offtake agreement with ThyssenKrupp Metallurgical Products GmbH (“ThyssenKrupp”) whereby ThyssenKrupp will purchase 50% of future ferroniobium production up to 3,750 metric tons from the Elk Creek property for an initial term of ten years from commencement of commercial production which may be extended by mutual agreement of the parties. The Agreement presupposes the Company obtaining project financing, obtaining all necessary approvals and constructing a mine at Elk Creek. Pursuant to the agreement, the Company granted ThyssenKrupp a non-transferable warrant to acquire 8,569,000 common shares of the Company at an exercise price of C$0.67 per common share, which expired on December 12, 2015. At June 30, 2016 the Company has outstanding exercisable warrants, as follows: Number Exercise Expiry Date 6,745,947 $ 0.65 November 10, 2016 182,910 0.85 February 27, 2017 2,714,000 1.00 February 27, 2017 3,125,000 0.72 December 22, 2018 9,150,285 0.75 January 19, 2019 21,918,142 On April 20, 2016, the Company announced an early warrant exercise program (the “Program”) designed to encourage the early exercise of (unlisted) share purchase warrants exercisable at C$0.65 that otherwise expire on November 10, 2016 (the “November 2016 Warrants”). The Program and its commencement were approved at a Special Meeting of Shareholders held on Tuesday May 17, 2016. The warrant exercise program closed on June 17, 2016, resulting in gross proceeds of C$4,807. A total of 7,394,822 C$0.65 share purchase warrants expiring November 10, 2016 were exercised during the incentive period, representing about 47.6% of all C$0.65 Warrants outstanding and 66% of warrant holders eligible to participate. Each holder who exercised one warrant during the program received 1.11029 Common Shares, representing one warrant share and 0.11029 of a Common Share, as the incentive portion. A total of 8,210,394 common shares were issued under the program, which was previously approved by our shareholders on May 17, 2016. The Company recognized a warrant expense of $535 in other operating expenses in the consolidated statement of operations related to the fair market value of the incentive shares issued. |